Medical Disclaimer
This article is for informational purposes only and doesn't constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider, including a psychiatrist or mental health professional, before starting, stopping, or changing any medication. If you or someone you know is experiencing suicidal thoughts, contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or go to your nearest emergency department. FormBlends is a licensed telehealth provider offering compounded medications under physician supervision.
Crisis Resources
If you're in immediate distress or having thoughts of self-harm:
988 Suicide and Crisis Lifeline: Call or text 988 (available 24/7)
Crisis Text Line: Text HOME to 741741
Emergency: Call 911 or go to your nearest emergency department
Last updated: March 25, 2026
Medical review date: March 25, 2026
This article cites evidence from the following sources: STEP 1-8 (semaglutide for obesity). SURMOUNT 1-4 (tirzepatide for obesity). SELECT (semaglutide cardiovascular outcomes). FDA safety review of GLP-1 receptor agonists (January 2024). EMA PRAC assessment of GLP-1 receptor agonists (April 2024). FDA Adverse Event Reporting System (FAERS) data. Scandinavian registry studies. U.S. claims database analyses. and published literature on GLP-1 neuroscience, neuroinflammation, and psychiatric pharmacology. Full references available upon request.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Ready when you are
Semax / Selank Blend
Focus and calm support in one cognitive peptide blend · From $229/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View Semax / Selank Blend →